ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

Published October 1, 2024

License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services

Dublin, Ireland, and Montreal, Canada – October 1, 2024 – ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Canadian research institution renowned for scientific innovation and technology transfer, today announced a non-exclusive CRISPR/Cas9 license agreement.

The agreement grants the university access to ERS’ CRISPR/Cas9 patent portfolio – including enabling the launch of two CRISPR/Cas9 screening facility platforms at UdeM’s Institute for Research in Immunology and Cancer.

Lynda Adam, PhD, Director of Technology Transfer, Innovation and Partnerships, Université de Montréal, said: “With the acquisition of this license, we have launched platform services that will broaden access to genome-wide CRISPR screening and data to the research community. Furthermore, this license enables UdeM researchers to carry out project collaborations and partnerships using CRISPR technology under certain conditions.”

John E. Milad, CEO, ERS Genomics, commented: “Université de Montréal has a reputation for making outstanding contributions to scientific innovation. Providing this license and access to the CVC patent portfolio has enabled the launch of screening platforms, which will play a role in uncovering new therapeutic targets and ultimately improve healthcare outcomes. We look forward to seeing the transformative impact of their work on global medical challenges.”

← Back to Movers & Shakers